Novavax, Inc. Aktie News

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.

Novavax, Inc. (NASDAQ:NVAX ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacobs - President, CEO & Director Ruxandra Draghia-Akli - EVP and Head of Research & Development John Charles Jacobs Are we ready to go? Are we live?

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines showed strong immune responses in some patients tested in a late-stage study, the company said on Wednesday.

Both vaccine candidates induced robust immune responses across all antigens tested No new safety signals were observed and both vaccine candidates were well tolerated consistent with past trials Novavax continues to pursue partnering opportunities to advance further development of these programs GAITHERSBURG, Md. , June 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced resul...

U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.

Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccine panel late on Monday.

Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.

Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.